Carbohydrate Metabolism in Kidney Disease and Kidney Failure

Nutritional Management of Renal Disease

Volumn , Issue , 2013, Pages 17-30

  Ritz, Eberhard ^a   Adamczak, Marcin ^b   Wiecek, Andrzej ^b  

^a Nierenzentrum   (Germany)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884060486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391934-2.00002-3     Document Type: Chapter

References (191)

1. Massry S.G., Smogorzewski M. Carbohydrate metabolism in renal failure. Nutritional management of renal disease 2007, 63-76. Williams and Wilkins, Baltimore. J.D. Kopple, S.G. Massry (Eds.).
2. DeFronzo R.A., Andres R., Edgar P., et al. Carbohydrate metabolism in uremia: a review. Medicine (Baltimore) 1973, 52:469-481.
3. DeFronzo R.A., Alvestrand A., Smith D., et al. Insulin resistance in uremia. J Clin Invest 1981, 67:563-568.
4. Westervelt F.B., Schreiner G.E. The carbohydrate intolerance of uremic patients. Ann Intern Med 1962, 57:266-276.
5. DeFronzo R.A., Alvertrand A. Glucose intolerance in uremia: site and mechanism. Am J Clin Nutr 1980, 33:1438-1445.
6. Shinohara K., Shoji T., Emoto M., et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:1894-1900.
7. Becker B., Kronenberg F., Kielstein J.T., et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005, 16:1091-1098.
8. Stumvoll M., Chintalapudi U., Perriello G., et al. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Inves 1995, 96:2528-2533.
9. Stumvoll M., Meyer C., Perriello G., et al. Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol 1998, 274:E817-E826.
10. Meyer C., Stumvoll M., Dostou J., et al. Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. Am J Physiol Endocrinol Metab 2002, 282:E428-E434.
11. Smith D., DeFronzo R.A. Insulin resistance in uremia mediated by postbinding defects. Kidney Int 1982, 22:54-62.
12. Weisinger J., Contreras N.E., Cajias J., et al. Insulin binding and glycolytic activity in erythrocytes from dialyzed and non-dialyzed uremic patients. Nephron 1988, 48:190-196.
13. Taylor R., Heaton A., Hetherington C.S., et al. Adipocyte insulin binding and insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Metabolism 1986, 35:430-435.
14. Pedersen O., Schmitz O., Hjollund E., et al. Postbinding defects of insulin action in human adipocytes from uremic patients. Kidney Int 1985, 27:780-784.
15. Maloff B.L., McCaleb M.L., Lockwood D.H. Cellular basis of insulin resistance in chronic uremia. Am J Physiol 1983, 245:E178-E184.
16. Bak J., Schmitz O., Sorensen S.S., et al. Activity of insulin receptor kinase and glycogen synthase in skeletal muscle from patients with chronic renal failure. Acta Endocrinol (Copenhagen) 1989, 121:744-750.
17. Cecchin F., Ittoop O., Sinha M.K., et al. Insulin resistance in uremia: insulin receptor kinase activity in liver and muscle from chronic uremic rats. Am J Physiol 1988, 254:E394-E401.
18. Bailey J.L., Mitch W.E. Pathophysiology of uremia. The Kidney 2004, 2139-2164. Saunders, Philadelpia. 7th ed. B. Brenner (Ed.).
19. White M.F. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002, 283:E413-E422.
20. Lee Y.H., White M.F. Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004, 27:361-370.
21. Folli F., Saad M.J., Kahn C.R. Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Acta Diabetol 1996, 33:185-192.
22. Rojas F.A., Hirata A.E., Saad M.J. Regulation of IRS-2 tyrosine phosphorylation in fasting and diabetes. Mol Cell Endocrinol 2001, 183:63-69.
23. Giorgino F., Pedrini M.T., Matera L., et al. Specific increase in p85alpha expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J Biol Chem 1997, 272:7455-7463.
24. May R.C., Kelly R.A., Mitch W.E. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia: the influence of metabolic acidosis. J Clin Invest 1987, 79:1099-1103.
25. Friedman J.E., Dohm G.L., Elton C.W., et al. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Physiol 1991, 261:E87-E94.
26. Kraus L.M., Traxinger R., Kraus A.P. Uremia and insulin resistance: N-carbamoyl-asparagine decreases insulin-sensitive glucose uptake in rat adipocytes. Kidney Int 2004, 65:881-887.
27. De Fronzo R.A., Tobin J.D., Rowe J.W., et al. Glucose intolerance in uremia: quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978, 62:425-435.
28. Kobayashi S., Maejima S., Ikeda T., et al. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2000, 15:65-70.
29. Heaton A., Taylor R., Johnston D.G., et al. Hepatic and peripheral insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Clin Sci 1989, 77:383-388.
30. Mak R.H. Insulin resistance in uremia: effect of dialysis modality. Pediatr Res 1996, 40:304-308.
31. McCaleb M.L., Wish J.B., Lockwood D.H. Insulin resistance in chronic renal failure. Endocrinol Res 1985, 11:113-125.
32. Dzurik R., Hupkova V., Cernacek P., et al. The isolation of an inhibitor of glucose utilization from the serum of uraemic subjects. Clin Chim Acta 1973, 46:77-83.
33. Spaia S., Pangalos M., Askepidis N., et al. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000, 84:320-325.
34. Tuzcu A., Bahceci M., Yilmaz E., et al. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res 2004, 36:716-720.
35. 3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998, 53:1353-1357.
36. Kautzky-Willer A., Pacini G., Barnas U., et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995, 47:200-206.
37. Gin H., Aparicio M., Potaux L., et al. Low protein and low phosphorus diet in patients with chronic renal failure: influence on glucose tolerance and tissue insulin sensitivity. Metabolism 1987, 36:1080-1085.
38. Gin H., Aparicio M., Potaux L., et al. Low-protein, low-phosphorus diet and tissue insulin sensitivity in insulin-dependent diabetic patients with chronic renal failure. Nephron 1991, 57:411-415.
39. Mak R., Turner C., Thompson T., et al. The effect of a low protein diet with amino acid/keto acid supplements on glucose metabolism in children with uremia. J Clin Endocrinol Metab 1986, 63:985-989.
40. Kuku S.F., Jaspan J.B., Emmanouel D.S., et al. Heterogeneity of plasma glucagon-circulating components in normal subjects and patients with chronic renal failure. J Clin Invest 1976, 58:742-750.
41. Emmanouel D.S., Jaspan J.B., Kuku S.F., et al. Pathogenesis and characterization of hyperglucagonemia in the uremic rat. J Clin Invest 1976, 58:1266-1272.
42. DeFronzo R.A., Tobin J., Boden G., et al. The role of growth hormone in the glucose intolerance of uremia. Acta Diabetol Lat 1979, 16:279-286.
43. Ijaiya K. Pattern of growth hormone response to insulin, arginine and haemodialysis in uraemic children. Eur J Pediatr 1979, 131:185-198.
44. Ross R.J., Goodwin F.J., Houghton B.J., et al. Alteration of pituitary-thyroid function in patients with chronic renal failure treated by haemodialysis or continuous ambulatory peritoneal dialysis. Ann Clin Biochem 1985, 22:156-160.
45. Ramirez G., Bittle P.A., Sanders H., et al. The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin. J Clin Endocrinol Metab 1994, 78:63-69.
46. Mak R.H. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 1998, 54:603-607.
47. Kraut J.A., Madias N.E. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011, 26:19-28.
48. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008, 118:2992-3002.
49. Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
50. Rocha V.Z., Folco E.J. Inflammatory concepts of obesity. Int J Inflam 2011, 2011:529061.
51. Hotamisligil G.S., Murray D.L., Choy L.N., et al. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994, 91:4854-4858.
52. Hotamisligil G.S. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27:S53-S55.
53. Ikizler T.A. Nutrition, inflammation and chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:162-167.
54. Chance W.T., Fischer J.E. Aphagic and adipsic effects of interleukin-1. Brain Res 1991, 568:261-264.
55. Kuhlmann M.K., Levin N.W. Potential interplay between nutrition and inflammation in dialysis patients. Contrib Nephrol 2008, 161:76-82.
56. Kalantar-Zadeh K., Kopple J.D., Humphreys M.H., et al. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1507-1519.
57. da Costa J.A., Ikizler T.A. Inflammation and insulin resistance as novel mechanisms of wasting in chronic dialysis patients. Semin Dial 2009, 22:652-657.
58. Folli F., Kahn C.R., Hansen H., et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100:2158-2169.
59. Folli F., Saad M.J., Velloso L., et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999, 107:133-139.
60. Satirapoj B., Yingwatanadej P., Chaichayanon S., et al. Effect of angiotensin II receptor blockers on insulin resistance in maintenance haemodialysis patients. Nephrology (Carlton) 2007, 12:342-347.
61. Trirogoff M.L., Shintani A., Himmelfarb J., et al. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3-4 chronic kidney disease patients. Am J Clin Nutr 2007, 86:1642-1648.
62. Ramos L.F., Shintani A., Ikizler T.A., et al. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008, 19:593-599.
63. Rea R., Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity?. Diabetes Obes Metab 2004, 6:163.
64. Kielstein J.T., Becker B., Graf S., et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003, 42:62-66.
65. Stuart C.A., Shangraw R.E., Prince M.J., et al. Bed-rest-induced insulin resistance occurs primarily in muscle. Metabolism 1988, 37:802-806.
66. Goldberg A.P., Hagberg J., Delmez J.A., et al. The metabolic and psychological effects of exercise training in hemodialysis patients. Am J Clin Nutr 1980, 33:1620-1628.
67. Goldberg A.P., Hagberg J.M., Delmez J.A., et al. Metabolic effects of exercise training in hemodialysis patients. Kidney Int 1980, 18:754-761.
68. Fadda G.Z., Hajjar S.M., Perna A.F., et al. On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest 1991, 87:255-261.
69. Fadda G.Z., Thanakitcharu P., Comunale R., et al. Impaired potassium-induced insulin secretion in chronic renal failure. Kidney Int 1991, 40:413-417.
70. Nakamura Y., Yoshida T., Kajiyama S., et al. Insulin release from column-perifused isolated islets of uremic rats. Nephron 1985, 40:467-469.
71. Oh H.Y., Fadda G.Z., Smogorzewski M., et al. Abnormal leucine-induced insulin secretion in chronic renal failure. Am J Physiol 1994, 267:F853-F860.
72. Mak R.H., Bettinelli A., Turner C., et al. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab 1985, 60:229-233.
73. Mak R.H., Turner C., Haycock G.B., et al. Secondary hyperparathyroidism and glucose intolerance in children with uremia. Kidney Int 1983, 24:S128-S133.
74. Fadda G.Z., Akmal M., Premdas F.H., et al. Insulin release from pancreatic islets: effects of CRF and excess PTH. Kidney Int 1988, 33:1066-1072.
75. Perna A.F., Fadda G.Z., Zhou X.J., et al. Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone. Am J Physiol 1990, 259:F210-F216.
76. Milner R.D. Stimulation of insulin secretion in vitro by essential amino acids. Lancet 1969, 1:1075-1076.
77. 2+-dependent phosphorylation of three protein concomitant with insulin secretion from HIT cells. Diabetes 1987, 36:864-871.
78. Mak R.H., Betinelli A., Turner C., et al. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab 1985, 60:229-233.
79. Mak R.H., Turner C., Haycock G.B., Chantler C. Secondary hyperparathyroidism and glucose intolerance in children with uremia. Kidney Int 1983, 24:S128-S133.
80. 3 receptors in chick pancreas and kidney cytosol. Endocrinology 1981, 108:140-149.
81. 3 in chick pancreas: a partial physical and functional characterization. J Steroid Biochem 1981, 16:385-395.
82. Roth J., Bonner-Weir S., Norman A.W., et al. Immunocytochemistry of vitamin D-dependent calcium binding protein in chick pancreas: exclusive localization in β cells. Endocrinology 1982, 110:2216-2218.
83. Narbaitz R., Stumpf W.E., Sar M. The role of autoradiographic and immunocytochemical techniques in the clarification of sites of metabolism and action of vitamin D. J Histochem Cytochem 1981, 29:91-100.
84. 3 deficiency inhibits pancreatic secretion of insulin. Science 1980, 209:823-825.
85. 3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986, 119:84-90.
86. Mak R.H. Intravenous 1, 25-dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992, 41:1049-1054.
87. 125I). Am J Physiol 1972, 223:1093-1096.
88. Rubenstein A.H., Mako M.E., Horwitz D.L. Insulin and the kidney. Nephron 1975, 15:306-326.
89. Rabkin R., Jones J., Kitabchi A.E. Insulin extraction from the renal peritubular circulation in the chicken. Endocrinology 1977, 101:1828-1833.
90. Rabkin R., Simon N.M., Steiner S., et al. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 1970, 282:182-187.
91. Rabkin R., Unterhalter S.A., Duckworth W.C. Effect of prolonged uremia on insulin metabolism by isolated liver and muscle. Kidney Int 1979, 16:433-439.
92. Meyer C., Stumvoll M., Dostou J., et al. Renal substrate exchange gluconeogenesis in normal postabsorptive humans. Am J Physiol 2002, 282:E428-E434.
93. Mather A., Pollock C. Glucose handling by the kidney. Kidney Int 2011, 79:S1-S6.
94. Garber A.J., Bier D.M., Cryer P.E., et al. Hypoglycemia in compensated chronic renal insufficiency: substrate limitations of gluconeogenesis. Diabetes 1974, 23:982-986.
95. Nadkarni M., Berns J.S., Rudnick M.R., et al. Hypoglycemia with hyperinsulinemia in a chronic hemodialysis patient following parathyroidectomy. Nephron 1992, 60:100-103.
96. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989, 18:103-121.
97. Moen M.F., Zhan M., Hsu V.D., et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1121-1127.
98. Jackson M.A., Holland M.R., Nicholas J., et al. Occult hypoglycemia caused by hemodialysis. Clin Nephrol 1999, 51:242-247.
99. Takahashi A., Kubota T., Shibahara N., et al. The mechanism of hypoglycemia caused by hemodialysis. Clin Nephrol 2004, 62:362-368.
100. Gonzalez A.R., Khurana R.C., Jung Y., et al. Enhanced response to tolbutamide in uremia. Acta Diabetol Lat 1972, 9:373-386.
101. Krepinsky J., Ingram A.J., Clase C.M. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000, 35:500-505.
102. Ferrannini E., Buzzigoli G., Bonadonna R., et al. Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
103. Eckel R.H., Yost T.J., Jensen D.R. Alterations in lipoprotein lipase in insulin resistance. Int J Obes Relat Metab Disord 1995, 19:S16-S21.
104. Chan M.K., Varghese Z., Moorhead J.F. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981, 19:625-637.
105. Roullet J.B., Lacour B., Drueke T. Partial correction of lipid disturbances by insulin in experimental renal failure. Contrib Nephrol 1986, 50:203-210.
106. Siew E.D., Ikizler T.A. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin Dial 2010, 23:378-382.
107. May R.C., Clark A.S., Goheer A., et al. Identification of specific defects in insulin-mediated muscle metabolism in acute uremia. Kidney Int 1985, 28:490-495.
108. Price S.R., Bailey J.L., Wang X., et al. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome pathway by a mechanism including gene transcription. J Clin Invest 1996, 98:1703-1708.
109. Mitch W.E. Insights into the abnormalities of chronic renal disease attributed to malnutrition. J Am Soc Nephrol 2002, 13:S22-S27.
110. Ritz E. Metabolic syndrome and kidney disease. Blood Purif 2008, 26:59-62.
111. Johnson R.J., Sanchez-Lozada L.G., Nakagawa T. The effect of fructose on renal biology and disease. J Am Soc Nephrol 2010, 21:2036-2039.
112. Kobayashi S., Maejima S., Ikeda T., et al. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2000, 15:65-70.
113. Chu P.L., Chiu Y.L., Lin J.W., et al. Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance. Blood Purif 2008, 26:213-220.
114. Williams M.E. Management of diabetes in dialysis patients. Curr Diab Rep 2009, 9:466-472.
115. Kalantar-Zadeh K., Derose S.F., Nicholas S., et al. Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr 2009, 19:33-37.
116. Sharma R., Rosner M.H. Glucose in the dialysate: Historical perspective and possible implications?. Hemodial Int 2008, 12:221-226.
117. Reilly J.B., Berns J.S. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial 2010, 23:163-168.
118. Schernthaner G., Ritz E., Schernthaner G.H. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. Nephrol Dial Transplant 2010, 25:2044-2047.
119. Sharif A. Current and emerging antiglycaemic pharmacological therapies: the renal perspective. Nephrology (Carlton) 2011, 16:468-475.
120. Szeto C.C., Chow K.M., Kwan B.C., et al. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis. Am J Kidney Dis 2007, 49:524-532.
121. Tuzcu A., Bahceci M., Yilmaz M.E., et al. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease. Saudi Med J 2005, 26:786-791.
122. de Moraes T.P., Fortes P.C., Ribeiro S.C., et al. Comparative analysis of lipid and glucose metabolism biomarkers in non-diabetic hemodialysis and peritoneal dialysis patients. J Bras Nefrol 2011, 33:173-179.
123. Lameire N., Matthys E., Matthys E., et al. Effects of long-term CAPD on carbohydrate and lipid metabolism. Clin Nephrol 1988, 30(Suppl. 1):53-58.
124. Wesołowski P., Saracyn M., Nowak Z., et al. Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. Pol Arch Med Wewn 2010, 120:54-57.
125. Fortes P.C., de Moraes T.P., Mendes J.G., et al. Insulin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int 2009, 29:S145-S148.
126. Gürsu E.M., Ozdemir A., Yalinbas B., et al. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients. Clin Nephrol 2006, 66:263-268.
127. Amici G., Orrasch M., Da Rin G., et al. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2001, 17:80-83.
128. Starzl T.E., Marchioro T.L., Rifkind D., et al. Factors in successful renal transplantation. Surgery 1964, 56:296-318.
129. Bodziak K.A., Hricik D.E. New-onset diabetes mellitus after solid organ transplantation. Transpl Int 2009, 22:519-530.
130. Bloom R.D., Crutchlow M.F. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol 2008, 3:S38-S48.
131. Cosio F.G., Kudva Y., van der Velde M., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005, 67:2415-2421.
132. Kasiske B.L., Snyder J.J., Gilbertson D., et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
133. Roth D., Milgrom M., Esquenazi V., et al. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989, 47:278-281.
134. Revanur V.K., Jardine A.G., Kingsmore D.B., et al. Infl{ligature}uence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001, 15:89-94.
135. Sharif A., Moore R., Baboolal K. Infl{ligature}uence of lifestyle modifi{ligature}cation in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008, 85:353-358.
136. Matas A.J., Gillingham K.J., Humar A., et al. Transplant diabetes mellitus and acute rejection: impact on kidney transplant outcome. Transplantation 2008, 85:338-343.
137. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
138. UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
139. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
140. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
141. Schneider C.A., Ferrannini E., Defronzo R., et al. Effect of pioglitazoneon cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008, 19:182-187.
142. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009, 63:912-929.
143. Nordio M., Limido A., Maggiore U., et al. Survival in patients treated by long-term dialysis compared with the general population. Am J Kidney Dis 2012, 59:819-828.
144. Morioka T., Emoto M., Tabata T., et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001, 24:909-913.
145. Oomichi T., Emoto M., Tabata T., et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006, 29:1496-1500.
146. Hayashino Y., Fukuhara S., Akiba T., et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007, 50:1170-1177.
147. c and survival in maintenance hemodialysis patients. Diabetes Care 2007, 30:1049-1055.
148. Drechsler C., Krane V., Ritz E., et al. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009, 120:2421-2428.
149. Williams M.E., Lacson E., Teng M., et al. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006, 70:1503-1509.
150. Schernthaner G., Stummvoll K.H., Muller M.M. Glycosylated haemoglobinin in chronic renal failure. Lancet 1979, 1(8119):774.
151. Inaba M., Okuno S., Kumeda Y., et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007, 18:896-903.
152. Peacock T.P., Shihabi Z.K., Bleyer A.J., et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008, 73:1062-1068.
153. Schernthaner G., Barnett A.H., Betteridge J. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010, 53:1258-1269.
154. Pilmore H.L. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010, 15:412-418.
155. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type II diabetes (UKPDS34). Lancet 1998, 352:854-865.
156. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
157. Evans J.M., Donnelly L.A., Emslie-Smith A.M., et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
158. Harrower A.D. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996, 31:111-119.
159. Nye H.J., Herrington W.G. Metformin: the safest hypoglycaemic agent in chronic kidney disease?. Nephron Clin Pract 2011, 118:c380-c383.
160. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
161. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004, 64:1339-1358.
162. Balant L., Zahnd G., Gorgia A., et al. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973, 9:331-338.
163. Boden G., Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006, 15:243-250.
164. Budde K., Neumayer H.H., Fritsche L., et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003, 55:368-374.
165. Chapelsky M.C., Thompson-Culkin K., Miller A.K., et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003, 43:252-259.
166. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
167. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007, 298:1189-1195.
168. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
169. Schneider C.A., Ferrannini E., Defronzo R., et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008, 19:182-187.
170. Ohtomo S., Izuhara Y., Takizawa S., et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007, 72:1512-1519.
171. Yang H.C., Deleuze S., Zuo Y., et al. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009, 20:2380-2388.
172. Lewis J.D., Ferrara A., Peng T., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
173. Piccinni C., Motola D., Marchesini G., et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011, 34:1369-1371.
174. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001, 358:1709-1716.
175. Lotfy M., Singh J., Kalász H., et al. Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. Open Med Chem J 2011, 5:82-92.
176. Marbury T.C., Ruckle J.L., Hatorp V., et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000, 67:7-15.
177. Gromada J., Brock B., Schmitz O., Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004, 95:252-262.
178. Linnebjerg H., Kothare P.A., Park S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007, 64:317-327.
179. Subbarayan S., Kipnes M. Sitagliptin: a review. Expert Opin Pharmacother 2011, 12:1613-1622.
180. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78:675-688.
181. Bergman A.J., Cote J., Yi B., Marbury T., et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007, 30:1862-1864.
182. Barnett A.H. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. adv Ther 2011, 28:447-459.
183. Graefe-Mody U., Friedrich C., Port A., et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011, 13:939-946.
184. Yamagishi S., Matsui T., Ueda S., et al. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab 2009, 10:159-163.
185. Spengler M., Schmitz H., Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus: a postmarketing surveillance study. Clin Drug Investig 2005, 25:651-659.
186. Ersoy A., Ersoy C., Altinay T. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus. Nephrol Dial Transplant 2006, 21:553-554.
187. Czock D., Aisenpreis U., Rasche F.M., et al. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther 2003, 41:492-497.
188. O'Mara N.B. Agents for the treatment of diabetes mellitus. Semin Dial 2010, 23:475-479.
189. Aronoff G.R., Berns J.S., Brier M.E., et al. Dosing Guidelines for Adults 1999, American College of Physicians, Philadelphia, Drug prescribing in renal failure; p. 84. 4th ed.
190. Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med 2009, 76:649-655.
191. Johnson J.A., Gale E.A. Diabetes, insulin use, and cancer risk: are observational studies part of the solution - or part of the problem?. Diabetes 2010, 59:1129-1131.